SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2002-01-0016. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0016v1 100/3/804    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hayashi, S. Articles by Flake, A. W. Search for Related Content PubMed PubMed Citation Articles by Hayashi, S. Articles by Flake, A. W. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2002, Vol. 100, No. 3, pp. 804-812 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion Satoshi Hayashi, William H. Peranteau, Aimen F. Shaaban, and Alan W. Flake From the Children's Institute for Surgical Science, The Children's Hospital of Philadelphia, PA. In utero hematopoietic stem cell transplantation (IUHSCTx) can achieve mixed hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning or immunosuppression. The primary limitation to the clinical application of IUHSCTx has been minimal donor cell engraftment, well below therapeutic levels for most target diseases. Donor lymphocyte infusion (DLI) has been used in postnatal circumstances of mixed chimerism as targeted immunotherapy to achieve a graft-versus-hematopoietic effect and to increase levels of donor cell engraftment. In this report we demonstrate in the murine model that a combined approach of IUHSCTx followed by postnatal DLI can convert low-level, mixed hematopoietic chimerism to complete donor chimerism across full major histocompatibility complex barriers with minimal risk for graft-versus-host disease (GVHD). Time-dated embryonic day 14 (E14) to E15 Balb/c (H-2Kd, CD45.2) fetuses underwent intraperitoneal injection of 5 × 106 T-cell-depleted B6 (H-2Kb, CD45.2) bone marrow cells. Chimeric recipients then received transplants at either 4 or 8 weeks of age with 1 of 3 doses (5, 15, or 30 × 106 cells) of donor congenic splenocytes (B6-Ly5.2/Cr, H-2Kb, CD45.1). The response to DLI was dose dependent, with conversion to complete donor peripheral blood chimerism in 100% of animals that received high-dose (30 × 106 cells) DLI. Only 1 of 56 animals receiving this dose succumbed to GVHD. This study directly supports the potential therapeutic strategy of prenatal tolerance induction to facilitate nontoxic postnatal cellular therapy and organ transplantation, and it has broad implications for the potential treatment of prenatally diagnosed genetic disorders. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. T. Durkin, K. A. Jones, D. Rajesh, and A. F. Shaaban Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras Blood, December 15, 2008; 112(13): 5245 - 5253. [Abstract] [Full Text] [PDF] P. Fiorina, M. Jurewicz, K. Tanaka, N. Behazin, A. Augello, A. Vergani, U. Von Adrian, N. R. Smith, M. H. Sayegh, and R. Abdi Characterization of Donor Dendritic Cells and Enhancement of Dendritic Cell Efflux With cc-Chemokine Ligand 21: A Novel Strategy to Prolong Islet Allograft Survival Diabetes, April 1, 2007; 56(4): 912 - 920. [Abstract] [Full Text] [PDF] W. H. Peranteau, M. Endo, O. O. Adibe, and A. W. Flake Evidence for an immune barrier after in utero hematopoietic-cell transplantation Blood, February 1, 2007; 109(3): 1331 - 1333. [Abstract] [Full Text] [PDF] W. H. Peranteau, M. Endo, O. O. Adibe, A. Merchant, P. W. Zoltick, and A. W. Flake CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation Blood, December 15, 2006; 108(13): 4268 - 4274. [Abstract] [Full Text] [PDF] H. Shibata, N. Ageyama, Y. Tanaka, Y. Kishi, K. Sasaki, S. Nakamura, S.-i. Muramatsu, S. Hayashi, Y. Kitano, K. Terao, et al. Improved Safety of Hematopoietic Transplantation with Monkey Embryonic Stem Cells in the Allogeneic Setting Stem Cells, June 1, 2006; 24(6): 1450 - 1457. [Abstract] [Full Text] [PDF] A. Frattini, H. C. Blair, M. G. Sacco, F. Cerisoli, F. Faggioli, E. M. Cato, A. Pangrazio, A. Musio, F. Rucci, C. Sobacchi, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero PNAS, October 11, 2005; 102(41): 14629 - 14634. [Abstract] [Full Text] [PDF] L. E. Shields, L. Gaur, P. Delio, J. Potter, A. Sieverkropp, and R. G. Andrews Fetal Immune Suppression as Adjunctive Therapy for In Utero Hematopoietic Stem Cell Transplantation in Nonhuman Primates Stem Cells, September 1, 2004; 22(5): 759 - 769. [Abstract] [Full Text] [PDF] M. E. Trigg Hematopoietic Stem Cells Pediatrics, April 1, 2004; 113(4/S1): 1051 - 1057. [Abstract] [Full Text] [PDF] B. W. Soper, M. D. Lessard, C. D. Jude, A. J. T. Schuldt, R. M. Bunte, and J. E. Barker Successful Allogeneic Neonatal Bone Marrow Transplantation Devoid of Myeloablation Requires Costimulatory Blockade J. Immunol., September 15, 2003; 171(6): 3270 - 3277. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020